Your browser doesn't support javascript.
loading
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
van Geel, Robin M J M; van Brummelen, Emilie M J; Eskens, Ferry A L M; Huijberts, Sanne C F A; de Vos, Filip Y F L; Lolkema, Martijn P J K; Devriese, Lot A; Opdam, Frans L; Marchetti, Serena; Steeghs, Neeltje; Monkhorst, Kim; Thijssen, Bas; Rosing, Hilde; Huitema, Alwin D R; Beijnen, Jos H; Bernards, René; Schellens, Jan H M.
Afiliación
  • van Geel RMJM; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • van Brummelen EMJ; Maastricht University Medical Centre, Department of Clinical Pharmacy and Toxicology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht, Netherlands.
  • Eskens FALM; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Huijberts SCFA; Centre for Human Drug Research, Leiden, Netherlands.
  • de Vos FYFL; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Lolkema MPJK; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands. s.huijberts@nki.nl.
  • Devriese LA; Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht, Netherlands.
  • Opdam FL; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Marchetti S; Department of Medical Oncology, UMC Utrecht Cancer Center, Utrecht, Netherlands.
  • Steeghs N; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands. f.opdam@nki.nl.
  • Monkhorst K; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Thijssen B; Department of Medical Oncology and Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Rosing H; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Huitema ADR; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Beijnen JH; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Bernards R; Department of Pharmacy, The Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Schellens JHM; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, Netherlands.
Br J Cancer ; 122(8): 1166-1174, 2020 04.
Article en En | MEDLINE | ID: mdl-32147669
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas p21(ras) / Quinasas de Proteína Quinasa Activadas por Mitógenos / Difenilamina / Quinazolinonas / Receptores ErbB / Mutación / Neoplasias Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Benzamidas / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas p21(ras) / Quinasas de Proteína Quinasa Activadas por Mitógenos / Difenilamina / Quinazolinonas / Receptores ErbB / Mutación / Neoplasias Tipo de estudio: Clinical_trials Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Año: 2020 Tipo del documento: Article País de afiliación: Países Bajos